Abstract 2838: Tumor-targeted interleukin-2 enhances the anti-cancer activity of multivalent OncoFAP radioligand therapeutics
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2838
Abstract: Radioligand Therapeutics (RLTs) are products composed of a tumor-targeting small organic ligand and a biocidal radioactive payload. The therapeutic potential of RLTs strongly depends on their uptake and residence time in tumors and in the… read more here.
Keywords: multivalent oncofap; tumor; cancer; radioligand therapeutics ... See more keywords
Abstract 5037: DARPins as powerful targeting agents for radioligand therapeutics
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5037
Abstract: The development of effective radioligand therapeutics (RLTs) is frequently hampered by the lack of high-quality targeting agents that selectively deliver radioactive payloads to the site of disease while sparing healthy tissues. Antibodies can have high… read more here.
Keywords: radioligand therapeutics; affinity; targeting agents; darpin ... See more keywords
Commercial and business aspects of alpha radioligand therapeutics
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.1070497
Abstract: Radioligand therapy (RLT) is gaining traction as a safe and effective targeted approach for the treatment of many cancer types, reflected by a substantial and growing commercial market (valued at $7.78 billion in 2021, with… read more here.
Keywords: radioligand therapeutics; business aspects; commercial business; radioligand ... See more keywords